Bacil Pharma Limited (BACPHAR.BO) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-93.7%

₹1.18

vs ₹18.79 price

Levered DCF

₹0.41

After debt service

Piotroski score

2 / 9

Weak

Altman Z-score

2.81

Grey zone

Rating

B-

Overall 3 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
P/E	43×	76.72×	-149.2×	-32.24×	-0.87×	-7.61×	-3.06×	-3.97×
P/B	2.7×	1.22×	7.24×	2.94×	2.76×	1.31×	0.69×	0.71×
P/S	0×	0×	0×	0×	0×	0×	0×	0×
EV / EBITDA	-270.7×	69.42×	-155.45×	-32.49×	-0.82×	-8.09×	-3.54×	-4.07×
Gross margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Current ratio	0.68×	17.21×	0.46×	8.19×	6.69×	0.11×	0.11×	0.21×
Debt / equity	0×	0.01×	0.08×	0.02×	0.03×	0.13×	0.12×	0.05×
Interest coverage	0×	-4,700×	-3,507.41×	-127.78×	-73.46×	-37.52×	-21.25×	-1,197.07×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Return on equity	6.3%	1.6%	-4.9%	-9.3%	-315.2%	-17.2%	-22.7%	-17.9%
Return on invested capital	-1.0%	-1.0%	-14.4%	-16.2%	-4.8%	-10.9%	-12.7%	-13.8%
Return on assets	5.7%	1.6%	-4.5%	-9.0%	-303.5%	-5.9%	-7.7%	-7.5%
Free cash flow yield	1.1%	1.3%	-0.6%	-4.6%	-118.7%	-21.9%	-39.3%	-22.4%
Earnings yield	2.3%	1.3%	-0.7%	-3.2%	-114.3%	-13.1%	-32.7%	-25.3%
Enterprise value	₹663.2M	₹283.5M	₹88.4M	₹32.2M	₹31.8M	₹19M	₹10.9M	₹13.6M
Net debt / EBITDA	2.32×	-6.6×	-1×	0.08×	0.05×	-0.33×	-0.41×	-0.02×
Cash conversion cycle (days)	0	-2,138	-656	-59	-388	-827	-1,487	-1,418